These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica. Liew DFL; Mackie SL; Tison A; Sattui SE; Yates M; Buchanan RRC; Owen CE Rheum Dis Clin North Am; 2024 May; 50(2):255-267. PubMed ID: 38670724 [TBL] [Abstract][Full Text] [Related]
4. Muscle involvement on 18F-FDG PET-CT in polymyalgia rheumatica. A controlled retrospective study of 101 patients. Wendling D; Sondag M; Giraud N; Chouk M; Boulahdour H; Prati C; Verhoeven F Joint Bone Spine; 2020 May; 87(3):225-228. PubMed ID: 32007650 [TBL] [Abstract][Full Text] [Related]
5. The effect of prednisolone and a short-term prednisolone discontinuation for the diagnostic accuracy of FDG-PET/CT in polymyalgia rheumatica-a prospective study of 101 patients. Nielsen AW; Hansen IT; Nielsen BD; Kjær SG; Blegvad-Nissen J; Rewers K; Sørensen CM; Hauge EM; Gormsen LC; Keller KK Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2614-2624. PubMed ID: 38563881 [TBL] [Abstract][Full Text] [Related]
6. Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica. van der Geest KSM; van Sleen Y; Nienhuis P; Sandovici M; Westerdijk N; Glaudemans AWJM; Brouwer E; Slart RHJA Rheumatology (Oxford); 2022 Mar; 61(3):1072-1082. PubMed ID: 34117743 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis. van der Geest KSM; Treglia G; Glaudemans AWJM; Brouwer E; Jamar F; Slart RHJA; Gheysens O Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1876-1889. PubMed ID: 33372248 [TBL] [Abstract][Full Text] [Related]
8. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group. Ghosh N; Couette N; van Binsbergen WH; Weinmann SC; Jivanelli B; Shea B; Bass AR; Benesova K; Bingham CO; Calabrese C; Cappelli LC; Chan KK; Choy E; Daoussis D; Goodman S; Hudson M; Jamal S; Leipe J; Lopez-Olivo MA; Suarez-Almazor M; van der Laken CJ; Meara AS; Liew D; Kostine M Semin Arthritis Rheum; 2023 Feb; 58():152110. PubMed ID: 36372016 [TBL] [Abstract][Full Text] [Related]
9. Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors. Manzo C; Isetta M Reumatologia; 2021; 59(1):62-63. PubMed ID: 33707798 [TBL] [Abstract][Full Text] [Related]
10. Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment. Palard-Novello X; Querellou S; Gouillou M; Saraux A; Marhadour T; Garrigues F; Abgral R; Salaün PY; Devauchelle-Pensec V Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):773-9. PubMed ID: 26753600 [TBL] [Abstract][Full Text] [Related]
11. Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature. Calabrese C; Cappelli LC; Kostine M; Kirchner E; Braaten T; Calabrese L RMD Open; 2019; 5(1):e000906. PubMed ID: 31168414 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of the 2012 EULAR/ACR classification criteria for polymyalgia rheumatica in Korean patients. Lee KA; Kim HS; Lee SH; Kim HR Int J Rheum Dis; 2020 Oct; 23(10):1311-1317. PubMed ID: 32715648 [TBL] [Abstract][Full Text] [Related]
14. Polymyalgia rheumatica: A case series from Colombia and analysis of Latin America. Toro-Gutiérrez CE; Cañas CA; Mantilla RD; Beltrán S; Pastrana-Gonzalez V; Vecino MJ; Rodriguez-Jimenez M; Rojas M J Transl Autoimmun; 2021; 4():100115. PubMed ID: 34485886 [TBL] [Abstract][Full Text] [Related]
15. Use of 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients affected by polymyalgia rheumatica and persistent increase of acute phase reactants. Colaci M; Dichiara J; Aprile ML; Ippolito M; Schinocca C; Guggino G; Malatino L Front Med (Lausanne); 2022; 9():1042620. PubMed ID: 36465900 [TBL] [Abstract][Full Text] [Related]
17. Diagnosing polymyalgia rheumatica on Yuge S; Nakatani K; Yoshino K; Koyama T Ann Nucl Med; 2018 Oct; 32(8):573-577. PubMed ID: 29948622 [TBL] [Abstract][Full Text] [Related]
18. PET-CT findings in patients with polymyalgia rheumatica without symptoms of cranial ischaemia. Lund-Petersen A; Voss A; Laustrup H Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975885 [TBL] [Abstract][Full Text] [Related]
19. Identification and Classification of Polymyalgia Rheumatica (PMR) and PMR-Like Syndromes Following Immune Checkpoint Inhibitors (ICIs) Therapy: Discussion Points and Grey Areas Emerging from a Systematic Review of Published Literature. Manzo C; Isetta M; Natale M; Castagna A Medicines (Basel); 2020 Nov; 7(11):. PubMed ID: 33153016 [No Abstract] [Full Text] [Related]
20. Ultrasound of shoulder and knee improves the accuracy of the 2012 EULAR/ACR provisional classification criteria for polymyalgia rheumatica. Kobayashi K; Nakagomi D; Kobayashi Y; Ajima C; Hanai S; Koyama K; Ikeda K Rheumatology (Oxford); 2022 Mar; 61(3):1185-1194. PubMed ID: 34164671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]